NeuroBo Pharmaceuticals Inc (NRBO)
4.470
-0.21
(-4.48%)
USD |
NASDAQ |
Jul 03, 16:00
NeuroBo Pharmaceuticals Research and Development Expense (Annual): 9.158M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.158M |
| December 31, 2022 | 2.778M |
| December 31, 2021 | 6.546M |
| December 31, 2020 | 21.87M |
| December 31, 2019 | 17.48M |
| Date | Value |
|---|---|
| December 31, 2018 | 13.88M |
| December 31, 2017 | 22.69M |
| December 31, 2016 | 8.74M |
| December 31, 2015 | 3.991M |
| December 31, 2014 | 0.052M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.778M
Minimum
2022
21.87M
Maximum
2020
11.57M
Average
9.158M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Altimmune Inc | 65.80M |
| Vanda Pharmaceuticals Inc | 76.82M |
| Viking Therapeutics Inc | 63.81M |
| vTv Therapeutics Inc | 13.60M |
| Rhythm Pharmaceuticals Inc | 134.95M |